TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2016 DA - 2016// TI - Cancer statistics, 2016 JO - CA Cancer J Clin VL - 66 UR - https://doi.org/10.3322/caac.21332 DO - 10.3322/caac.21332 ID - Siegel2016 ER - TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2015 DA - 2015// TI - Cancer statistics, 2015 JO - CA Cancer J Clin VL - 65 UR - https://doi.org/10.3322/caac.21254 DO - 10.3322/caac.21254 ID - Siegel2015 ER - TY - JOUR AU - van Hagen, P. PY - 2012 DA - 2012// TI - Preoperative chemoradiotherapy for esophageal or junctional cancer JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1112088 DO - 10.1056/NEJMoa1112088 ID - van Hagen2012 ER - TY - JOUR AU - Davies, A. R. PY - 2014 DA - 2014// TI - Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2014.55.9070 DO - 10.1200/JCO.2014.55.9070 ID - Davies2014 ER - TY - JOUR AU - Holscher, A. H. PY - 2014 DA - 2014// TI - Prognostic classification of histopathologic response to neoadjuvant therapy in esophageal adenocarcinoma JO - Ann Surg VL - 260 UR - https://doi.org/10.1097/SLA.0000000000000964 DO - 10.1097/SLA.0000000000000964 ID - Holscher2014 ER - TY - JOUR AU - Berger, A. C. PY - 2005 DA - 2005// TI - Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.05.017 DO - 10.1200/JCO.2005.05.017 ID - Berger2005 ER - TY - JOUR AU - Chirieac, L. R. PY - 2005 DA - 2005// TI - Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation JO - Cancer VL - 103 UR - https://doi.org/10.1002/cncr.20916 DO - 10.1002/cncr.20916 ID - Chirieac2005 ER - TY - JOUR AU - Donohoe, C. L. AU - Ryan, A. M. AU - Reynolds, J. V. PY - 2011 DA - 2011// TI - Cancer cachexia: mechanisms and clinical implications JO - Gastroenterol Res Pract VL - 2011 UR - https://doi.org/10.1155/2011/601434 DO - 10.1155/2011/601434 ID - Donohoe2011 ER - TY - JOUR AU - Shaikh, T. PY - 2015 DA - 2015// TI - Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer JO - Ann Thorac Surg VL - 99 UR - https://doi.org/10.1016/j.athoracsur.2014.08.033 DO - 10.1016/j.athoracsur.2014.08.033 ID - Shaikh2015 ER - TY - JOUR AU - van Rossum, P. S. PY - 2016 DA - 2016// TI - The incremental value of subjective and quantitative assessment of 18F-FDG PET for the prediction of pathologic complete response to preoperative Chemoradiotherapy in esophageal Cancer JO - J Nucl Med VL - 57 UR - https://doi.org/10.2967/jnumed.115.163766 DO - 10.2967/jnumed.115.163766 ID - van Rossum2016 ER - TY - JOUR AU - Piessen, G. PY - 2013 DA - 2013// TI - Is there a role for surgery for patients with a complete clinical response after chemoradiation for esophageal cancer? An intention-to-treat case-control study JO - Ann Surg VL - 258 UR - https://doi.org/10.1097/SLA.0000000000000228 DO - 10.1097/SLA.0000000000000228 ID - Piessen2013 ER - TY - JOUR AU - Lee, J. L. PY - 2004 DA - 2004// TI - A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma JO - Ann Oncol VL - 15 UR - https://doi.org/10.1093/annonc/mdh219 DO - 10.1093/annonc/mdh219 ID - Lee2004 ER - TY - JOUR AU - Yuan, H. PY - 2016 DA - 2016// TI - PET/CT in the evaluation of treatment response to neoadjuvant chemoradiotherapy and prognostication in patients with locally advanced esophageal squamous cell carcinoma JO - Nucl Med Commun VL - 37 UR - https://doi.org/10.1097/MNM.0000000000000527 DO - 10.1097/MNM.0000000000000527 ID - Yuan2016 ER - TY - JOUR AU - Hellmann, M. D. PY - 2014 DA - 2014// TI - Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(13)70334-6 DO - 10.1016/S1470-2045(13)70334-6 ID - Hellmann2014 ER - TY - JOUR AU - Bruzzi, J. F. PY - 2007 DA - 2007// TI - Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy JO - Cancer VL - 109 UR - https://doi.org/10.1002/cncr.22397 DO - 10.1002/cncr.22397 ID - Bruzzi2007 ER - TY - JOUR AU - Elliott, J. A. PY - 2014 DA - 2014// TI - Value of CT-PET after neoadjuvant chemoradiation in the prediction of histological tumour regression, nodal status and survival in oesophageal adenocarcinoma JO - Br J Surg VL - 101 UR - https://doi.org/10.1002/bjs.9670 DO - 10.1002/bjs.9670 ID - Elliott2014 ER - TY - JOUR AU - Cheedella, N. K. PY - 2013 DA - 2013// TI - Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort JO - Ann Oncol VL - 24 UR - https://doi.org/10.1093/annonc/mds617 DO - 10.1093/annonc/mds617 ID - Cheedella2013 ER - TY - JOUR AU - Nagrath, D. PY - 2011 DA - 2011// TI - Metabolomics for mitochondrial and cancer studies JO - Biochim Biophys Acta VL - 1807 UR - https://doi.org/10.1016/j.bbabio.2011.03.006 DO - 10.1016/j.bbabio.2011.03.006 ID - Nagrath2011 ER - TY - JOUR AU - Cao, D. L. PY - 2011 DA - 2011// TI - Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine JO - Prostate Cancer Prostatic Dis VL - 14 UR - https://doi.org/10.1038/pcan.2011.2 DO - 10.1038/pcan.2011.2 ID - Cao2011 ER - TY - JOUR AU - Sreekumar, A. PY - 2009 DA - 2009// TI - Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression JO - Nature VL - 457 UR - https://doi.org/10.1038/nature07762 DO - 10.1038/nature07762 ID - Sreekumar2009 ER - TY - JOUR AU - Yan, H. PY - 2009 DA - 2009// TI - IDH1 and IDH2 mutations in gliomas JO - N Engl J Med VL - 360 UR - https://doi.org/10.1056/NEJMoa0808710 DO - 10.1056/NEJMoa0808710 ID - Yan2009 ER - TY - JOUR AU - Spratlin, J. L. AU - Serkova, N. J. AU - Eckhardt, S. G. PY - 2009 DA - 2009// TI - Clinical applications of metabolomics in oncology: a review JO - Clin Cancer Res VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-08-1059 DO - 10.1158/1078-0432.CCR-08-1059 ID - Spratlin2009 ER - TY - JOUR AU - Hanahan, D. AU - Weinberg, R. A. PY - 2011 DA - 2011// TI - Hallmarks of cancer: the next generation JO - Cell VL - 144 UR - https://doi.org/10.1016/j.cell.2011.02.013 DO - 10.1016/j.cell.2011.02.013 ID - Hanahan2011 ER - TY - JOUR AU - Certo, M. PY - 2006 DA - 2006// TI - Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members JO - Cancer Cell VL - 9 UR - https://doi.org/10.1016/j.ccr.2006.03.027 DO - 10.1016/j.ccr.2006.03.027 ID - Certo2006 ER - TY - JOUR AU - Potter, D. S. AU - Letai, A. PY - 2016 DA - 2016// TI - To prime, or not to prime: that is the question JO - Cold Spring Harb Symp Quant Biol VL - 81 UR - https://doi.org/10.1101/sqb.2016.81.030841 DO - 10.1101/sqb.2016.81.030841 ID - Potter2016 ER - TY - JOUR AU - Ryan, J. A. AU - Brunelle, J. K. AU - Letai, A. PY - 2010 DA - 2010// TI - Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes JO - Proc Natl Acad Sci U S A VL - 107 UR - https://doi.org/10.1073/pnas.0914878107 DO - 10.1073/pnas.0914878107 ID - Ryan2010 ER - TY - JOUR AU - Ni Chonghaile, T. PY - 2011 DA - 2011// TI - Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy JO - Science VL - 334 UR - https://doi.org/10.1126/science.1206727 DO - 10.1126/science.1206727 ID - Ni Chonghaile2011 ER - TY - JOUR AU - Montero, J. PY - 2015 DA - 2015// TI - Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy JO - Cell VL - 160 UR - https://doi.org/10.1016/j.cell.2015.01.042 DO - 10.1016/j.cell.2015.01.042 ID - Montero2015 ER - TY - JOUR AU - Stachler, M. D. PY - 2015 DA - 2015// TI - Paired exome analysis of Barrett's esophagus and adenocarcinoma JO - Nat Genet VL - 47 UR - https://doi.org/10.1038/ng.3343 DO - 10.1038/ng.3343 ID - Stachler2015 ER - TY - JOUR AU - Muller, P. A. AU - Vousden, K. H. PY - 2014 DA - 2014// TI - Mutant p53 in cancer: new functions and therapeutic opportunities JO - Cancer Cell VL - 25 UR - https://doi.org/10.1016/j.ccr.2014.01.021 DO - 10.1016/j.ccr.2014.01.021 ID - Muller2014 ER - TY - JOUR AU - Galluzzi, L. PY - 2008 DA - 2008// TI - Targeting p53 to mitochondria for cancer therapy JO - Cell Cycle VL - 7 UR - https://doi.org/10.4161/cc.7.13.6222 DO - 10.4161/cc.7.13.6222 ID - Galluzzi2008 ER - TY - JOUR AU - Madani, K. PY - 2010 DA - 2010// TI - Prognostic value of p53 mutations in oesophageal adenocarcinoma: final results of a 15-year prospective study JO - Eur J Cardiothorac Surg VL - 37 UR - https://doi.org/10.1016/j.ejcts.2009.12.018 DO - 10.1016/j.ejcts.2009.12.018 ID - Madani2010 ER - TY - JOUR AU - Kandioler, D. PY - 2014 DA - 2014// TI - The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 research group study JO - J Thorac Cardiovasc Surg VL - 148 UR - https://doi.org/10.1016/j.jtcvs.2014.06.079 DO - 10.1016/j.jtcvs.2014.06.079 ID - Kandioler2014 ER - TY - JOUR AU - Bruzzi, J. F. PY - 2006 DA - 2006// TI - Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT JO - J Nucl Med VL - 47 ID - Bruzzi2006 ER - TY - JOUR AU - Lawrence, M. S. PY - 2013 DA - 2013// TI - Mutational heterogeneity in cancer and the search for new cancer-associated genes JO - Nature VL - 499 UR - https://doi.org/10.1038/nature12213 DO - 10.1038/nature12213 ID - Lawrence2013 ER -